Remove 2026 Remove Drug Development Remove Packaging
article thumbnail

CPHI Pharma Awards 2023 finalists announced

European Pharmaceutical Review

Catalent: Case Management Services for Cell/Gene Therapies Cipla: Digital Innovation at Cipla Global Supply Chain Thermo Fisher Scientific: mySupply Platform Packaging Bilcare Limited: Elite PVC-free Compact Barrier Coldform Blister GASPOROX AB: AutoMAP Pharma IMA S.p.A.:

Packaging 119
article thumbnail

Five potential EU regulatory changes impacting the life sciences industry in 2023

European Pharmaceutical Review

Launch of the EU pharmaceutical package The European Commission plans to commence initiatives relating to the European Pharmaceutical Strategy (strategy) with the publication of the revised EU pharmaceutical package scheduled during the first quarter of 2023. of the MDR and Article 110.4

Packaging 117
article thumbnail

Legislative Update: Congress Extends Funding for Patient Programs

Putting Patients First Blog

The goal of the rare pediatric disease PRV program is to incentivize drug development for rare pediatric diseases. billion through fiscal year 2026. With the funding deadline occurring after the November elections, the next round of negotiations will be impacted by the election results. Under the CR, the Fund distributes $3.2